$LLY News and Market Events
Every $LLY story Market Flux has tracked.
- Market Flux Event
FDA Approves Eli Lilly Onswik as First Once-Weekly Basal Insulin for Type 2 Diabetes
The U.S. Food and Drug Administration approved Eli Lilly's Onswik, generic name insulin efsitora alfa-gobe, as a once-weekly basal insulin injection for adults living with type 2 diabetes…
- Unusual Volume
Novo Nordisk Stock Falls Up to 7.4% as 2030 Strategy and $23 Billion Pipeline Target Disappoint Investors
Novo Nordisk shares plunged as much as 7.4% on Monday after CEO Mike Doustdar used a Capital Markets Day in London to lay out a long-term growth strategy that failed to calm investor…
- Market Flux Event
FDA Accepts Cogent Biosciences NDA for Bezuclastinib as Novo Nordisk Rebrands Amid Lilly Competition
Cogent Biosciences secured a key regulatory milestone as the FDA accepted its New Drug Application for bezuclastinib in patients with Advanced Systemic Mastocytosis, assigning a PDUFA…
- Top Mover
Morgan Stanley Hosts Major Healthcare Conference, Expands Bitcoin Holdings Past $609 Million and Downgrades Stellantis
Morgan Stanley's 24th Annual Global Healthcare Conference dominated the firm's activity on September 14, drawing presentations from dozens of companies including Eli Lilly, Pfizer, Johnson…
- Market Flux Event
Dozens of Healthcare and Biotech Companies Showcase Pipelines and Launch Plans at Morgan Stanley, Jefferies and H.C. Wainwright Conferences
September 14, 2026 saw a broad wave of healthcare and biotech presentations across three major investor conferences, with the Morgan Stanley 24th Annual Global Healthcare Conference drawing…
- Unusual Volume
Novartis Shares Crash 14% to 52-Week Low After Three Drug Trial Failures in One Week
Novartis suffered a devastating session on Tuesday, September 8, with its U.S.-listed shares tumbling roughly 14% to close at $137.70, a fresh 52-week low, after two major late-stage…
- Market Flux Event
Trump Announces Drug Pricing Deals With Nine More Pharma Companies, Expanding Most Favored Nation Push
President Trump announced on August 31 that his administration has struck drug pricing agreements with nine additional pharmaceutical and biotech companies, committing them to sell…
- Market Flux Event
FDA Expands Mounjaro Label to Reduce Heart Attack and Stroke Risk in Type 2 Diabetes Patients
The FDA approved an expanded label for Eli Lilly's Mounjaro (tirzepatide) to reduce major adverse cardiovascular events, including heart attack and stroke, in high-risk patients with type 2…
- Top Mover
Eli Lilly Hits All-Time High as Stock Surges 4% and Deal With Amplitude Expands RNA Vaccine Pipeline
Eli Lilly shares climbed 4.0% on August 19, 2026, reaching a record intraday high of $1,249.95 as a broad biopharma rally, triggered by Moderna's cancer-vaccine breakthrough, lifted the…
- Most Active
OmniAb Signs Eli Lilly Ion Channel Deal Worth Up to $370M, Raises 2026 Cash Guidance
OmniAb struck a global collaboration and license agreement with Eli Lilly for a new ion channel drug discovery program, with OmniAb eligible to receive an upfront payment plus up to $370…
- Market Flux Event
Eli Lilly Wins European Approval for Weight Loss Pill Foundayo as BMY Scores FDA Nod for Myeloma Drug
Eli Lilly secured the first European regulatory approval for its oral weight loss pill Foundayo in the United Kingdom, intensifying a direct battle with Novo Nordisk, whose oral Wegovy was…
- Top Mover
Eli Lilly's Oral Weight-Loss Pill Foundayo Wins First European Approval in the UK
Britain's Medicines and Healthcare products Regulatory Agency approved Eli Lilly's oral GLP-1 pill orforglipron, branded Foundayo, on August 10, making the UK the first European country to…
- Market Flux Event
Eli Lilly Wins UK Approval for Oral Weight-Loss Pill Foundayo as Biotech Sector Sees Wave of Catalysts
Eli Lilly's oral weight-loss pill orforglipron, branded Foundayo, secured its first European regulatory approval in Britain on August 10, extending the drug's commercial footprint beyond…